[{"address1": "Lilly Corporate Center", "city": "Indianapolis", "state": "IN", "zip": "46285", "country": "United States", "phone": "317 276 2000", "website": "https://www.lilly.com", "industry": "Drug Manufacturers - General", "industryKey": "drug-manufacturers-general", "industryDisp": "Drug Manufacturers - General", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; collaboration with AdvanCell to advance novel targeted alpha therapies for the treatment of cancer; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.", "companyOfficers": [{"maxAge": 1, "name": "Mr. David A. Ricks", "age": 56, "title": "Chairman, CEO & President", "yearBorn": 1968, "fiscalYear": 2023, "totalPay": 6285660, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Daniel M. Skovronsky M.D., Ph.D.", "age": 51, "title": "EVP, Chief Scientific Officer and President of Lilly Research Laboratories & Lilly immunology", "yearBorn": 1973, "fiscalYear": 2023, "totalPay": 3819307, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Anat  Hakim J.D.", "age": 55, "title": "Executive VP, General Counsel & Secretary", "yearBorn": 1969, "fiscalYear": 2023, "totalPay": 2814807, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jacob S. Van Naarden", "age": 39, "title": "Executive VP & President of Loxo", "yearBorn": 1985, "fiscalYear": 2023, "totalPay": 2384307, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Lucas E. Montarce", "age": 47, "title": "Executive VP & CFO", "yearBorn": 1977, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Donald A. Zakrowski", "title": "Senior VP of Finance & Chief Accounting Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Diogo  Rau", "age": 49, "title": "EVP & Chief Information and Digital Officer", "yearBorn": 1975, "fiscalYear": 2023, "totalPay": 1056809, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Eric  Dozier", "age": 56, "title": "Executive Vice President of Human Resources & Diversity", "yearBorn": 1968, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jeffrey N. Simmons", "age": 57, "title": "Senior VP & President of Elanco Animal Health", "yearBorn": 1967, "fiscalYear": 2023, "totalPay": 1729146, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. W. Darin Moody", "title": "SVP of Global Active Pharmaceutical Ingredient, Dry Products Mfg & Continuous Improvement Division", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 4, "compensationRisk": 2, "shareHolderRightsRisk": 9, "overallRisk": 7, "governanceEpochDate": 1738368000, "compensationAsOfEpochDate": 1703980800, "irWebsite": "http://investor.lilly.com/", "maxAge": 86400, "priceHint": 2, "previousClose": 870.36, "open": 869.1, "dayLow": 841.57, "dayHigh": 873.3699, "regularMarketPreviousClose": 870.36, "regularMarketOpen": 869.1, "regularMarketDayLow": 841.57, "regularMarketDayHigh": 873.3699, "dividendRate": 6.0, "dividendYield": 0.0070999996, "exDividendDate": 1739491200, "payoutRatio": 0.4441, "fiveYearAvgDividendYield": 1.19, "beta": 0.412, "trailingPE": 71.91397, "forwardPE": 28.998684, "volume": 2627936, "regularMarketVolume": 2627936, "averageVolume": 3771553, "averageVolume10days": 3648840, "averageDailyVolume10Day": 3648840, "bid": 842.1, "ask": 846.0, "bidSize": 900, "askSize": 1000, "marketCap": 759265492992, "fiftyTwoWeekLow": 711.4, "fiftyTwoWeekHigh": 972.53, "priceToSalesTrailing12Months": 16.856571, "fiftyDayAverage": 798.7426, "twoHundredDayAverage": 846.2438, "trailingAnnualDividendRate": 5.2, "trailingAnnualDividendYield": 0.005974539, "currency": "USD", "enterpriseValue": 787058262016, "profitMargins": 0.23511, "floatShares": 897166329, "sharesOutstanding": 899315968, "sharesShort": 6767383, "sharesShortPriorMonth": 6098698, "sharesShortPreviousMonthDate": 1735603200, "dateShortInterest": 1738281600, "sharesPercentSharesOut": 0.0075, "heldPercentInsiders": 0.0034599998, "heldPercentInstitutions": 0.83362997, "shortRatio": 1.79, "shortPercentOfFloat": 0.0085, "impliedSharesOutstanding": 899315968, "bookValue": 15.825, "priceToBook": 53.350395, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "earningsQuarterlyGrowth": 1.014, "netIncomeToCommon": 10590000128, "trailingEps": 11.74, "forwardEps": 22.66, "lastSplitFactor": "2:1", "lastSplitDate": 876960000, "enterpriseToRevenue": 17.474, "enterpriseToEbitda": 41.979, "52WeekChange": 0.11726177, "SandP52WeekChange": 0.22894537, "lastDividendValue": 1.5, "lastDividendDate": 1739491200, "exchange": "NYQ", "quoteType": "EQUITY", "symbol": "LLY", "underlyingSymbol": "LLY", "shortName": "Eli Lilly and Company", "longName": "Eli Lilly and Company", "firstTradeDateEpochUtc": 76253400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "7b37be39-dfde-3602-b0e4-4d76cf52143b", "messageBoardId": "finmb_285467", "gmtOffSetMilliseconds": -18000000, "currentPrice": 844.27, "targetHighPrice": 1190.0, "targetLowPrice": 620.0, "targetMeanPrice": 981.4704, "targetMedianPrice": 1000.0, "recommendationMean": 1.75, "recommendationKey": "buy", "numberOfAnalystOpinions": 26, "totalCash": 3518400000, "totalCashPerShare": 3.912, "ebitda": 18749065216, "totalDebt": 31230699520, "totalRevenue": 45042700288, "debtToEquity": 218.081, "revenuePerShare": 49.823, "returnOnEquity": 0.84099996, "grossProfits": 36624400384, "earningsGrowth": 1.018, "revenueGrowth": 0.447, "grossMargins": 0.8131, "ebitdaMargins": 0.41625, "operatingMargins": 0.41987, "financialCurrency": "USD", "trailingPegRatio": 0.8546, "__fetch_time": "2025-02-15"}]